Synthego is a genome engineering company that enables the acceleration of life science research and development in the pursuit of improved human health.
The company leverages machine learning, automation, and gene editing to build platforms for science at scale. With its foundations in engineering disciplines, the company’s full-stack platform vertically integrates proprietary hardware, software, bioinformatics, chemistries, and molecular biology to advance both basic research and therapeutic development programs.
By providing access to its cutting-edge genome engineering tools, Synthego is working in a collaborative effort with UCSF’s QBI Coronavirus Research Group (QCRG) to further investigate the role of human proteins that interact with SARS-CoV-2 and help elucidate potential therapeutic targets, as described in their recent Nature publication, “A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.” See their COVID-19 resources page here.
